SUBSCRIBE
SUBSCRIBE
News   Policy

Discovery Laboratories to File Surfaxin Response in 4 Weeks

September 24, 2008 | 
1 min read

Sept 24 (Reuters) - Discovery Laboratories Inc said it expects to submit a complete response to the U.S. Food and Drug Administration’s concerns on its experimental lung drug for infants within the next four weeks.

Regulatory
MORE ON THIS TOPIC
ASD autism neurodevelopmental spectrum disorder, deficits in social communication and interaction, brain with impairment, hypersensitivity and abnormalities
Editorial
Kennedy’s Hunt for a Connection Between Vaccines and Autism Is a Sham
April 17, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Vaccines
HHS Pulls Funding for GeoVax’s Next-Gen COVID-19 Vaccine
April 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Entrance to the U.S. Department of Health and Human Services in Washington, DC
Government
Trump Eyes $40 Billion Budget Cut for HHS: Reports
April 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Diverse cultures, international communication concept. Human silhouette with speech bubbles.
Regulatory
Former FDA Officials Sound Alarm: Visible Changes May Be ‘Tip of the Iceberg’
April 16, 2025
 · 
3 min read
 · 
Heather McKenzie